← Eichor
Condition: Advanced Cholangiocarcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Cholangiocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06298968Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Phase 2 · 2 location(s) · Case Comprehensive Cancer Center · NCT07146646Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
Phase 1 · 2 location(s) · University of Maryland, Baltimore · NCT06546969Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Phase 1/Phase 2 · 11 location(s) · Genfit · NCT05874414Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced
Phase 2 · 1 location(s) · West China Hospital · NCT06859684Liver Transplantation in Intrahepatic Cholangiocarcinoma
Phase N/A · 2 location(s) · Rutgers, The State University of New Jersey · NCT06140134Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Chol
Phase 2 · 1 location(s) · Fudan University · NCT06860477Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07025174Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Phase 3 · 1 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT05342194Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
Phase 2 · 1 location(s) · West China Hospital · NCT06438822Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06126406PULSAR Combined With Immunotherapy and Chemotherapy
Phase 1/Phase 2 · 1 location(s) · Wang Xin · NCT07291947Cosiporfin Sodium for Injection Photodynamic Therapy
Phase 2 · 1 location(s) · Shanghai Guangsheng Biopharmaceutical Co., Ltd · NCT07398339Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06010862SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Phase 1/Phase 2 · 24 location(s) · Bold Therapeutics, Inc. · NCT04421820Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05010681A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Phase 1 · 2 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06043466Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Phase 1 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07614061Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unr
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06852287Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta
Phase 1/Phase 2 · 38 location(s) · Institut de Recherches Internationales Servier · NCT06501625Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Chol
Phase 2 · 1 location(s) · Fudan University · NCT07070700Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Phase 1 · 4 location(s) · Tyra Biosciences, Inc · NCT06160752Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
Phase 2 · 6 location(s) · National Cancer Institute, Naples · NCT06341764Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma
Phase 2 · 1 location(s) · CNBG-Virogin Biotech (Shanghai) Ltd. · NCT06746480An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Phase 3 · 84 location(s) · Servier Affaires Médicales · NCT05876754AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Phase 1 · 2 location(s) · University of Southern California · NCT05791448Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Phase 2 · 41 location(s) · UNICANCER · NCT06529718
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.